Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
Clinical trial NCT04178967 · COMPLETED
Trial details
- NCT number
- NCT04178967
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-29
- Primary completion
- 2021-07-12
- Enrollment
- 445
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.